Psychiatric NP Scope of Practice for General Psychiatry in Texas

If you’re a psychiatrist, PMHNP, or prescriber considering telehealth—or already managing patients online—one question keeps coming up: Can I legally prescribe controlled substances like Adderall, Xanax, or buprenorphine via telehealth?

The short answer: Yes, for now—and possibly for good, but the rules are changing.

As of early 2026, federal telehealth flexibilities remain in place through December 31, 2026, allowing psychiatrists to prescribe Schedule II–V controlled substances via video consultation without an initial in-person exam. But the DEA is finalizing permanent rules that could reshape how we practice telepsychiatry, including new registration requirements and state-by-state variations you need to understand.

If you’re weighing whether to expand your telehealth practice—or join a platform that handles patient acquisition for you—this guide breaks down exactly what’s allowed today, what’s coming tomorrow, and how to stay compliant while building a sustainable psychiatric practice.

The Current State: Federal Telehealth Flexibilities Extended Through 2026

Here’s where we stand: The DEA and HHS announced a fourth extension of COVID-era telehealth prescribing rules through December 31, 2026. This means you can continue prescribing controlled substances (Schedules II–V) via telemedicine without requiring patients to have an initial in-person visit—as long as you conduct an appropriate evaluation through interactive audio-video technology.

This extension was necessary because the DEA’s original proposal to restrict telehealth prescribing (allowing only 30-day supplies of Schedule III–V without in-person visits, and zero Schedule II) faced massive pushback. Over 38,000 comments from providers and patients made it clear: restricting telehealth access to psychiatric medications would disrupt care for millions.

What this means for your practice right now:

• You can initiate treatment with stimulants (Adderall, Vyvanse) for ADHD via video consultation
• You can prescribe benzodiazepines (Xanax, Klonopin) for anxiety disorders through telehealth
• You can start patients on buprenorphine for opioid use disorder without an in-person exam
• You must use real-time, two-way audio-visual communication for the initial evaluation (phone-only generally doesn’t count, except for buprenorphine in specific circumstances)

Important caveat: If a patient has ever been seen in person by any healthcare provider (not necessarily you), there’s no federal restriction on prescribing controlled medications via telehealth for that patient. The Ryan Haight Act’s in-person requirement only applies to patients who have never had an in-person medical evaluation.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Coming: New DEA Telemedicine Rules Proposed for 2026

The DEA isn’t just extending temporary rules—they’re building a permanent framework. In January 2025, the DEA announced three proposed rules that could significantly impact telepsychiatry:

1. Buprenorphine for Opioid Use Disorder

The DEA proposes allowing clinicians to prescribe buprenorphine via telehealth (including audio-only) for up to 6 months before requiring an in-person evaluation. This is actually more permissive than current law and acknowledges how effective telemedicine has been for addiction treatment. After 6 months, patients would need an in-person visit to continue treatment.

For psychiatrists providing addiction services, this is good news—it codifies what’s been working and gives clear guardrails.

2. Special Telemedicine Registration for Schedule II Prescribing

This is the big one. The DEA proposes creating a ‘Special Telemedicine Prescriber Registration’ that would allow qualified providers to prescribe controlled substances to new patients via telehealth without any in-person exam requirement.

For Schedule III–V medications, any qualified prescriber could apply. For Schedule II (stimulants, etc.), the DEA is initially limiting eligibility to:

• Board-certified psychiatrists
• Hospice/palliative care physicians
• Physicians at long-term care facilities
• Pediatricians (for limited cases)

Psychiatrists are explicitly included. If finalized, this means you could obtain a special registration to prescribe Adderall, Ritalin, and other Schedule II medications via telehealth indefinitely, without ever requiring an in-person visit.

The catch? Telehealth platforms would be required to register with the DEA for the first time, and the DEA is proposing a national Prescription Drug Monitoring Program (PDMP) to track prescriptions across state lines. These are accountability measures in response to cases where some telehealth companies over-prescribed stimulants.

3. VA System Special Provision

A third rule would allow any VA telehealth provider to prescribe controlled substances to a patient who had an in-person exam with any VA clinician, treating the entire VA system as one entity. This doesn’t directly affect private practice, but it signals the DEA’s willingness to create pathways that prioritize continuity of care.

Timeline: These rules are in the comment period as of early 2026. Finalization could happen mid-to-late 2026. Until then, the temporary extension remains in effect.

State-by-State Variations: Why Your Location (and Your Patients’) Matters

Federal law sets the floor, but states can impose stricter rules—and many do. Let’s break down what psychiatrists need to know in key states:

Texas: Strict NP Limits, Physician Freedom

• Psychiatrists: Full authority to prescribe all controlled substances via telehealth under current federal rules. Texas defers to federal law for controlled substance prescribing.
• PMHNPs: Cannot prescribe Schedule II medications (Adderall, Ritalin, etc.) in outpatient settings—only in hospitals or hospice. Texas NPs also require physician supervision for all practice. If you’re operating in Texas, you’ll need MDs to handle stimulant prescriptions.
• PDMP requirement: Must check Texas PMP before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol.
• Chronic pain caveat: Cannot prescribe controlled substances for chronic pain via telehealth without an in-person exam (though this rarely affects psychiatry).

Florida: Psychiatric Exception to Schedule II Ban

• Florida generally prohibits Schedule II prescribing via telehealth—except for four categories, including psychiatric treatment. This means you can prescribe Adderall for ADHD via telehealth in Florida.
• Out-of-state providers can register as Florida telehealth providers without a full license, but they face the same prescribing rules.
• PMHNPs in Florida require a collaborative agreement with a psychiatrist—no independent practice for psychiatric NPs yet.
• Must check E-FORCSE (Florida’s PDMP) before prescribing any controlled substance.

California: Transitioning to NP Independence

• No state-specific telehealth prescribing restrictions beyond federal law.
• Must check CURES PDMP before first Schedule II–IV prescription and every 4 months thereafter.
• PMHNPs are transitioning to full practice authority—experienced NPs can practice independently in group settings now, and solo practice will be fully allowed by 2026.
• 100% e-prescribing required for all prescriptions since 2022.

New York: Strictest PDMP, Most NP Freedom

• Must check PMP before every Schedule II, III, or IV prescription (one of the strictest PDMP mandates).
• 100% e-prescribing required (including non-controlled meds).
• PMHNPs with >3,600 clinical hours can practice fully independently, including prescribing controlled substances. Below that threshold, they need a collaborative agreement.
• No special state restrictions on telehealth controlled substance prescribing.

Pennsylvania: Collaborative Requirements for NPs

• No comprehensive telehealth statute yet, but practice is allowed under general medical regulations.
• PMHNPs must have collaborative agreements with at least two physicians for prescriptive authority.
• NPs can prescribe Schedule II for up to 30 days, Schedule III–IV for up to 90 days, under collaboration.
• Must check PA PDMP before prescribing opioids or benzodiazepines.

Illinois: Full Practice Available, With Quirks

• PMHNPs can obtain Full Practice Authority (FPA) after 4,000 hours and additional training—then practice independently.
• Even with FPA, must have a physician consultation relationship to prescribe Schedule II opioids or benzodiazepines beyond 30-day supplies.
• Must check IL PMP before prescribing opioids.
• E-prescribing required for all controlled substances as of January 2023.

Key takeaway: If you’re practicing across multiple states (as many telehealth psychiatrists do), you need to understand each state’s rules. A PMHNP who’s fully independent in New York might need a collaborating physician in Texas. A psychiatrist who can freely prescribe Adderall via telehealth in California faces stricter PDMP requirements in New York.

Psychiatrist vs. PMHNP Scope: What’s the Difference?

Psychiatrists (MD/DO) have uniform authority across all states: full independent practice, full prescriptive authority for all controlled substances (assuming proper DEA registration and state licensure). Your scope is limited only by standard of care and your training.

PMHNPs face a patchwork:

• Full Practice States (New York post-3,600 hours, California transitioning, Illinois with FPA): Can evaluate, diagnose, and prescribe independently, including controlled substances.
• Reduced Practice States (Pennsylvania, Ohio): Need collaborative agreements but can do most clinical work with physician oversight on paper.
• Restricted Practice States (Texas, Florida, South Carolina): Require ongoing physician supervision and may have significant prescribing limits (e.g., no Schedule II in Texas outpatient settings).

This matters for telehealth platforms: a platform operating in Texas needs to ensure PMHNPs have supervising physicians, or rely on psychiatrists for stimulant prescriptions. A platform in New York can recruit experienced PMHNPs who function exactly like psychiatrists for most purposes.

Compliance Essentials: What Every Telepsychiatry Provider Must Do

Beyond federal and state prescribing rules, here’s your compliance checklist:

1. PDMP Checks

Most states now mandate checking the Prescription Drug Monitoring Program before prescribing controlled substances:

• California: Before first Schedule II–IV Rx and every 4 months
• New York: Before every Schedule II–IV prescription
• Texas: Before opioids, benzos, barbiturates, carisoprodol
• Florida: Before any controlled substance for patients ≥16
• Pennsylvania: Before opioids/benzos
• Illinois: Before opioids (recommended for others)

Many states now participate in interstate PDMP data sharing, so you can often see prescriptions from neighboring states.

2. E-Prescribing

Almost all states require electronic prescribing of controlled substances:

• California, New York: All prescriptions (controlled and non-controlled)
• Texas, Florida, Pennsylvania, Illinois: Controlled substances must be e-prescribed

Your telehealth platform should have this built in—paper scripts are essentially obsolete for telepsychiatry.

3. DEA Training Requirement

As of 2023, all DEA registrants (or those renewing) must complete a one-time 8-hour training on substance use disorder and appropriate prescribing. This came from the Medication Access and Training Expansion (MATE) Act. Board-certified addiction psychiatrists are exempt (their certification counts), but most general psychiatrists and PMHNPs need to satisfy this requirement.

4. State Licensure

You must be licensed in every state where your patients are located. Telehealth is considered to occur where the patient is. Some states offer pathways:

• Florida: Out-of-state telehealth registration (limited, no Schedule II prescribing except for psychiatric care)
• IMLC states (California, Texas, Illinois, Pennsylvania—not New York): Interstate Medical Licensure Compact can streamline obtaining multiple state licenses for physicians
• No shortcuts for NPs: PMHNPs generally need individual state licenses (a few states are in the Nurse Licensure Compact, but APRN practice authority still varies)

5. Documentation Standards

Document your telehealth evaluations thoroughly:

• Mental status exam findings
• Diagnostic reasoning
• Why the prescribed medication is appropriate
• That the patient was evaluated via audio-video (specify the technology used)
• Any PDMP findings reviewed
• Follow-up plan

Thorough documentation protects you if state boards or DEA review your practice. After high-profile cases of telehealth companies over-prescribing stimulants with minimal evaluations, regulators are watching more closely.

The Economics of Telehealth: Why Platforms Beat DIY Marketing

Many psychiatrists interested in telehealth face a choice: build your own practice infrastructure or join a platform that handles patient acquisition.

The reality of DIY patient acquisition:

• SEO takes 6–12 months of consistent investment before generating meaningful traffic. Most solo providers don’t have the expertise or patience.
• Google Ads for mental health keywords cost $15–40+ per click. A realistic cost per booked patient through PPC is $200–400+ when you factor in clicks that don’t convert, no-shows from cold leads, and time spent qualifying leads.
• Directory listings (Psychology Today, Zocdoc) charge monthly fees and per-booking fees. Zocdoc charges $35–100+ per booking, plus subscription costs. You compete with hundreds of other providers on the same page.
• True patient acquisition cost through DIY marketing is typically $200–500+ when you include agency fees, ad spend, staff time, failed campaigns, and months of SEO investment.

The platform model (like Klarity Health) flips this equation:

• Pay per appointment, not per click. You only pay when a qualified patient actually books with you—no wasted ad spend.
• Pre-qualified patients already matched to your specialty and availability. No cold leads or low-intent clicks.
• Built-in telehealth infrastructure. No separate platform costs or IT headaches.
• Both insurance and cash-pay patient flow, giving you volume and flexibility.
• Zero upfront marketing spend. Instead of spending $3,000–5,000/month gambling on marketing channels with uncertain results, you pay a standard listing fee per new patient lead—guaranteed ROI.

For most providers—especially those starting out, scaling up, or expanding to new states—a platform that handles patient acquisition removes the risk entirely. You focus on what you’re trained to do: evaluating patients and providing excellent care. The platform handles everything else.

What to Watch For in 2026 and Beyond

The telehealth prescribing landscape is stabilizing, but stay alert for:

1. DEA’s final rules (likely mid-to-late 2026): If the special telemedicine registration is finalized, psychiatrists should apply early to ensure uninterrupted Schedule II prescribing after the temporary extension expires.

2. State legislative changes: States like Pennsylvania may finally pass comprehensive telehealth laws. Texas and Florida may (or may not) expand PMHNP scope. Track your state’s medical and nursing board updates.

3. Platform DEA registration requirements: If finalized, telehealth platforms will need DEA registration. Choose platforms that are prepared to comply—Klarity Health is closely monitoring these developments.

4. Interstate licensure expansion: More states joining IMLC or creating out-of-state provider pathways could make multi-state practice easier.

5. Enforcement actions: State boards are cracking down on providers who prescribe controlled substances without adequate evaluations. Document thoroughly, follow PDMP requirements, and avoid ‘prescription mill’ red flags (e.g., very short evaluations, no follow-ups, high-dose stimulants to new patients without supporting diagnosis).

FAQ: Common Questions from Psychiatrists About Telehealth Prescribing

Q: Can I prescribe Adderall via telehealth to a new patient in 2026?
A: Yes, under the current federal extension through December 31, 2026. You must conduct an appropriate evaluation via audio-video consultation, document thoroughly, and follow your state’s PDMP and licensing requirements. If the DEA’s special registration is finalized, you may need that registration to continue prescribing Schedule II via telehealth after the extension expires.

Q: What happens if the DEA extension expires and permanent rules aren’t finalized?
A: Historically, the DEA has extended multiple times to avoid disrupting care. If the extension expires without permanent rules, federal law would revert to the Ryan Haight Act requirement: an in-person exam before prescribing controlled substances (with very limited exceptions). This is unlikely, but providers should have contingency plans (e.g., arranging in-person visits or partnering with local providers).

Q: Can PMHNPs prescribe stimulants via telehealth?
A: It depends on the state. In New York (with 3,600+ hours), California (transitioning), and Illinois (with FPA), yes. In Texas, no—PMHNPs cannot prescribe Schedule II in outpatient settings at all. In Florida, only with a collaborative physician and meeting the psychiatric treatment exception.

Q: Do I need a separate DEA number for each state I practice in?
A: Yes. If you’re prescribing controlled substances to patients in multiple states, you need a DEA registration in each state (tied to a practice address in that state, or using your state medical license number). You’ll also need full licensure in each state.

Q: Can I use audio-only (phone) for telehealth prescribing?
A: Generally, no—except for buprenorphine for opioid use disorder, which the DEA has allowed via audio-only under the proposed rules. For other controlled substances, you should use interactive audio-video technology for the initial evaluation and any visits where prescribing decisions are made. Audio-only might be acceptable for follow-ups with established patients in some states (e.g., California, New York allow audio-only for mental health in certain cases), but video is the safer standard.

Q: What’s the difference between the ‘X-waiver’ and the new DEA training requirement?
A: The X-waiver (DATA 2000 waiver) required providers to get special permission to prescribe buprenorphine for opioid use disorder. That was eliminated in 2023—any DEA-registered psychiatrist or NP can now prescribe buprenorphine without a waiver. Instead, all DEA registrants must now complete an 8-hour training on substance use disorder and pain management as part of their DEA renewal (one-time requirement).

Q: How do I know if my state requires PDMP checks?
A: Check your state medical board or nursing board’s controlled substance prescribing rules. Most states now mandate PDMP checks before prescribing opioids and benzodiazepines; some (like New York) require it for all controlled substances. Your state PDMP website usually has provider resources explaining the requirements.

Q: If I join a telehealth platform, who handles compliance with all these rules?
A: A reputable platform (like Klarity Health) ensures the infrastructure supports compliance—e.g., credentialing you in appropriate states, integrating e-prescribing, providing documentation templates, and alerting you to state-specific requirements. But ultimate responsibility for clinical decisions and compliance rests with the licensed provider. Choose platforms that provide robust compliance support and stay updated on regulatory changes.

Ready to Expand Your Psychiatric Practice via Telehealth?

The regulations are complex, but the opportunity is clear: telehealth is here to stay, and psychiatrists who understand the rules can build thriving, compliant practices.

Whether you’re a psychiatrist, PMHNP, or prescriber looking to reach more patients without the headache of marketing, patient acquisition, and compliance infrastructure, Klarity Health offers a turnkey solution.

With Klarity, you get:

• Pre-qualified patients matched to your specialty and schedule
• Pay-per-appointment model (no upfront marketing costs)
• Built-in telehealth platform and e-prescribing
• Support for multi-state practice and compliance
• Both insurance and cash-pay patient flow

Stop gambling on marketing channels with uncertain ROI. Join a platform that guarantees qualified patients and lets you focus on care.

→ Explore Klarity Health’s provider network and see how you can start seeing more patients—today.

Citations

1. U.S. Department of Health and Human Services (HHS). ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026.’ Press Release, January 2, 2026. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration (DEA). ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Care and Protect Patient Safety.’ Press Release, January 16, 2025. https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. Florida Legislature. Florida Statutes §456.47: ‘Use of Telehealth to Provide Services.’ Online Sunshine, 2025 edition. http://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html

4. Akerman LLP. ‘Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth.’ Healthcare Law & Regulation Bulletin, March 2023. https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html

5. Texas Medical Board. ‘Prescriptive Authority FAQs: Prescribing and Supervision.’ Updated 2024. https://www.tmb.texas.gov/resources/for-applicants-and-licensees/prescribing-and-supervision

Last updated: February 2026. Federal and state telehealth regulations continue to evolve. Providers should verify current rules with their state medical/nursing boards and monitor DEA announcements for final rule implementations.

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices